Neoleukin Therapeutics Inc
Research Neoleukin Therapeutics Inc (NGNE) on Bullrun: market cap USD 646.52M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNGNE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 646.52M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 30.93M
- Free cash flow-USD 26.40M
Valuation Snapshot
latest market cap is USD 646.52M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 90.35M | -USD 78.36M | n/a | -4.24 | USD 103.85M | USD 10.96M | USD 264.89M |
| FY2024 | USD 925.00K | -USD 75.14M | -USD 71.41M | n/a | -4.28 | USD 136.59M | USD 14.24M | USD 310.38M |
| FY2023 | USD 0 | -USD 36.32M | -USD 51.74M | n/a | -100.07 | USD 148.21M | USD 16.26M | USD 186.02M |
| FY2022 | n/a | -USD 55.19M | -USD 55.05M | n/a | -1.04 | USD 82.02M | n/a | -USD 145.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 646.52M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 319.09M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 339.58M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 248.52M | n/a | n/a | n/a |
About Neoleukin Therapeutics Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neoleukin Therapeutics Inc's market cap?
Neoleukin Therapeutics Inc's market capitalization is USD 646.52M.
What does Neoleukin Therapeutics Inc do?
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.